ACT Onco® + Report

PATIENT		
Identifier: 蘇楨喻		Patient ID: 28271014
Date of Birth: Aug 23, 1963		Gender: Female
Diagnosis: Cholangiocarcinoma		
ORDERING PHYSICIAN		
Name: 陳明晃醫師		Tel: 886-228712121
Facility: 臺北榮總		
Address: 臺北市北投區石牌路二段 201 號		
SPECIMEN		
Specimen ID: 11122499F	Collection site: Liver	Type: FFPE tissue
Date received: Jul 28, 2023	Lab ID: AA-23-04942	D/ID: NA

ABOUT ACTOnco®+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (InDels) (≤ 15 nucleotides) and large-scale genomic alterations like copy number alterations (CNAs). The test also includes an RNA test, detecting fusion transcripts of 13 genes.

SUMMARY FOR ACTIONABLE VARIANTS

VARIANTS/BIOMARKERS WITH EVIDENCE OF CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Probable Effects in Patient's Cancer Type		Probable Sensitive in Other Cancer Types
	Sensitive	Resistant	
Not detected			

VARIANTS/BIOMARKERS WITH POTENTIAL CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Possibly Sensitive	Possibly Resistant
BAP1 Q392*	Olaparib, Rucaparib	-

Note:

- The above summary tables present genomic variants and biomarkers based on the three-tiered approach proposed by US FDA for reporting tumor profiling NGS testing. "Variants/biomarkers with evidence of clinical significance" refers to mutations that are widely recognized as standard-of-care biomarkers (FDA level 2/AMP tier 1). "Variants/biomarkers with potential clinical significance" refers to mutations that are not included in the standard of care but are informational for clinicians, which are commonly biomarkers used as inclusion criterial for clinical trials (FDA level 3/AMP tier 2).
- The therapeutic agents and possible effects to a given drug are based on mapping the variants/biomarkers with ACT Genomics clinical knowledge database. The mapping results only provide information for reference, but not medical recommendation.
- Please refer to corresponding sections for more detailed information about genomic alteration and clinical relevance listed above.

ACT Onco®+ Report

TESTING RESULTS

VARIANT(S) WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Allele Frequency
BAP1	Q392*	24.3%
PBRM1	Splice donor	18.9%

- Copy Number Alterations

Chromosome	Gene	Variation	Copy Number
Chr13	*BRCA2, RB1*	Heterozygous deletion	1
Chr16	*TSC2*	Heterozygous deletion	1
Chr4	*FBXW7*	Heterozygous deletion	1
Chr9	*PTCH1, TSC1*	Heterozygous deletion	1

- Fusions

Fusion Gene & Exon	Transcript ID
No fusion gene detected in this sample	

- Immune Checkpoint Inhibitor (ICI) Related Biomarkers

Biomarker	Results
Tumor Mutational Burden (TMB)	1.3 muts/Mb
Microsatellite Instability (MSI)	Microsatellite stable (MSS)

Note:

- Variant(s) enlisted in the SNV table may currently exhibit no relevance to treatment response prediction. Please refer to INTERPRETATION for more biological information and/or potential clinical impacts of the variants.
- Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on 38% tumor purity.
- For more therapeutic agents which are possibly respond to heterozygous deletion of genes listed above, please refer to APPENDIX for more information.
- TMB was calculated by using the sequenced regions of ACTOnco®+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at ≥ 7.5 mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is < 30%.

ACT Onco® + Report

THERAPEUTIC IMPLICATIONS

TARGETED THERAPIES

Genomic Alterations	Therapies	Effect
Level 3B		
BAP1 Q392*	Olaparib, Rucaparib	**sensitive**

Therapies associated with benefit or lack of benefit are based on biomarkers detected in this tumor and published evidence in professional guidelines or peer-reviewed journals.

Level	Description
1	FDA-recognized biomarkers predictive of response or resistance to FDA approved drugs in this indication
2	Standard care biomarkers (recommended by the NCCN guideline) predictive of response or resistance to FDA approved drugs in this indication
3A	Biomarkers predictive of response or resistance to therapies approved by the FDA or NCCN guideline in a different cancer type
3B	Biomarkers that serve as inclusion criteria for clinical trials (minimal supportive data required)
4	Biomarkers that show plausible therapeutic significance based on small studies, few case reports, or preclinical studies

ACT Onco® + Report

IMMUNE CHECKPOINT INHIBITORS (ICIs)

No genomic alterations detected to confer sensitivity or lack of benefit to immune checkpoint therapies.

- Other Biomarkers with Potential Clinical Effects for ICIs

Genomic Alterations	Potential Clinical Effects
Not detected	

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

CHEMOTHERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to chemotherapies.

HORMONAL THERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to hormonal therapies.

OTHERS

Pharmacogenomic implication

Gene	Detection Site	Genotype	Drug Impact	Level of Evidence*
UGT1A1	rs4148323	AG	Irinotecan-based regimens	Level 1B
Clinical Interpretation: Patients with the AG genotype and cancer who are treated with irinotecan-based regimens may have an increased risk of diarrhea and neutropenia as compared to patients with the GG genotype, or a decreased risk of diarrhea and neutropenia compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of diarrhea and neutropenia.				

* Level of evidence was defined by PharmGKB (https://www.pharmgkb.org/page/clinAnnLevels)

Level 1A: Clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation.
Level 1B: Clinical annotations describe variant-drug combinations with a high level of evidence supporting the association but no variant-specific prescribing guidance in an annotated clinical guideline or FDA drug label.
Level 2A: Variants in Level 2A clinical annotations are found in PharmGKB's Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely.

Note:
Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

ACT Onco® + Report

VARIANT INTERPRETATION

BAP1 Q392*

Biological Impact

Breast cancer type 1 susceptibility protein (BRCA1)-associated protein (BAP1) encodes an enzyme with ubiquitin carboxyl hydrolase activity involved in the regulation of cell cycle, transcription, and double-strand DNA repair[1][2][3]. BAP1 acts as a tumor suppressor by forming a complex with BRCA1[4]. BAP1 is a haploinsufficient tumor suppressor with one copy loss may lead to weak protein expression and is related to renal cell carcinoma (RCC)[5]. Inactivating mutations of BAP1 were frequently observed in uveal melanoma with high metastatic risk, malignant mesothelioma and other carcinoma types, including a subtype of renal cell carcinoma and intrahepatic cholangiocarcinoma[2][6][7][8][9][10][11].

Q392* mutation results in a premature truncation of the BAP1 protein at amino acid 392 (UniProtKB). This mutation is predicted to lead to a loss of BAP1 function, despite not having been characterized in the literature.

Therapeutic and prognostic relevance

In a Phase II trial (MiST1; NCT03654833), rucaparib demonstrated manageable toxicity and clinical activity in patients with relapsed malignant mesothelioma that were negative for BAP1 (n=23), BRCA1 (n=13), or both (n=10), resulting in a 12-week disease control rate (DCR) of 58% (15/26), a 24-week DCR of 23% (6/26), and an objective response rate of 11.5% (3/26)[12].The loss of BAP1 was shown to be associated with increased sensitivity to PARP inhibitor, olaparib, in renal cell carcinoma (RCC)[8]and mesothelioma cell lines[13]. However, no difference in sensitivity to the PARP inhibitor niraparib (MK4827) was observed between BAP1-mutant and wild-type mesothelioma cell[2]. BAP1 deficiency was also linked to a high tumor grade and was correlated with metastasis development in uveal melanoma[6].

An open-label, non-randomized, Phase II study (NCT03207347) has been initiated, aimed at investigating the use of niraparib in mesothelioma, uveal melanoma, renal cell carcinoma, and cholangiocarcinoma patients with tumors known to have mutations in BAP1 and other selected DNA double-strand break repair pathway genes. BAP1 loss of function mutation has been selected as an inclusion criteria for the trial examining olaparib in urothelial cancer (NCT03375307) and malignant mesothelioma (NCT04515836).

PBRM1 Splice donor

Biological Impact

The PBRM1 gene encodes the protein BAF180 tumor suppressor, which is a component of the nucleosome-remodeling complex switching defective/sucrose non-fermenting (SWI/SNF)[14]. Loss of PBRM1 activity is associated with chromosomal instability[15]. PBRM1, BAP1 and SETD2 are three frequently altered tumor suppressor genes on chromosome 3p in a region that is deleted in over 90% of clear cell renal cell carcinoma (ccRCC)[16][17].

PBRM1 c.138+1G>C is a variant located at the splice donor region, which may result in the exon skipping.

Therapeutic and prognostic relevance

Biallelic loss or loss-of-function mutation of PBRM1 has been shown to correlate with clinical benefit in clear cell renal cell carcinoma (ccRCC), melanoma, lung cancer, bladder cancer, and head and neck squamous carcinoma (HNSCC) patients treated with immune checkpoint inhibitors[18][19].

Decreased expression of PBRM1 has been shown to predict unfavorable clinical outcome in patients with ccRCC[20].

BRCA2 Heterozygous deletion

Biological Impact

The BRCA2 gene encodes a tumor suppressor involved in the homologous recombination pathway for double-strand DNA repair[21]. BRCA2 has been implicated as a haploinsufficient gene with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological functions[22]. BRCA2 germline mutations confer an increased lifetime risk of developing breast, ovarian, prostate and pancreatic cancer, limited reports of related gastric cancer, and Fanconi anemia subtype D1-associated risk of brain cancer, medulloblastoma, pharyngeal cancer, chronic lymphocytic leukemia and acute myeloid leukemia[23]. Somatic mutations in BRCA2 are highest in colorectal, non-small cell lung cancer (NSCLC), and ovarian cancers[24].

Therapeutic and prognostic relevance

Multiple PARP inhibitors, including olaparib, rucaparib, niraparib, and talazoparib, have been approved by the U.S. FDA for the treatment of cancer. Olaparib is approved for multiple settings in advanced ovarian cancer, metastatic breast cancer with BRCA mutations, metastatic pancreatic cancer, and mCRPC with BRCA mutation or HRR gene mutations, including BRCA. Rucaparib is approved for maintenance treatment of recurrent ovarian cancer with BRCA mutations and mCRPC with BRCA mutations. Niraparib is approved for maintenance treatment of advanced ovarian cancer and recurrent ovarian cancer with BRCA mutations. Talazoparib is approved for locally advanced or metastatic breast cancer with BRCA mutations and mCRPC with HRR gene mutations, including BRCA.

According to the NCCN guidelines, rucaparib is recommended as recurrence therapy for patients with BRCA-mutated ovarian cancer who have been treated with multiple lines of chemotherapy. It is also recommended as maintenance therapy for patients with metastatic pancreatic cancer who have undergone prior platinum-based therapy and harbor germline or somatic BRCA mutations. Additionally, niraparib is recommended as maintenance therapy for ovarian cancer patients with BRCA mutations.

FBXW7 Heterozygous deletion

Biological Impact

The F-box/WD repeat-containing protein 7 (FBXW7) gene encodes a protein that belongs to the SCF (SKP1-CUL1-F-box protein) E3 ligase complex. FBXW7 is recognized as a tumor suppressor which is involved in the negative regulation of oncogenes such as c-Myc[25][26], c-Jun[27], cyclin E[28], Notch family members[29][30], Aurora-A[31], mTOR[32], KLF5[33], and MCL-1[34]. Inactivating FBXW7 mutation or copy number loss may result in the accumulation of oncoproteins and therefore lead to malignant transformation[35]. FBXW7 is a haploinsufficient tumor suppressor gene with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological functions[33][34][36].

Therapeutic and prognostic relevance

Clinical efficacy of mTOR inhibitors was seen in patients harboring aberrations in the FBXW7 gene (one patient with refractory fibrolamellar hepatocellular carcinoma, and one patient with lung adenocarcinoma)[37][38]. Moreover, in vitro assay also suggested that loss or inactivation of FBXW7 may confer sensitivity to mTOR inhibitor[32].

Preclinical studies suggested that mutations or loss of FBXW7 were associated with regorafenib and oxaliplatin resistance in CRC cell lines and gefitinib resistance in lung cancer cells[39][40][41][42].

Retrospective studies have indicated that a relatively low expression level of FBXW7 is an independent prognostic marker of poor survival for patients with hepatocellular carcinoma, lung adenocarcinoma and squamous cell carcinoma[43][41].

PTCH1 Heterozygous deletion

Biological Impact

The PTCH1 (protein patched homolog 1) gene encodes a multi-pass transmembrane receptor for sonic hedgehog (shh), a tumor suppressor that acts to repress shh signaling in the absence of ligand[44]. Inactivation of PTCH1 results in hedgehog ligand-independent activation of SMO, causing a downstream activation of the pathway and lead to the neoplastic growth[45][46]. Recurrent PTCH1 mutations have been reported in sporadic basal cell carcinoma (BCCs) and medulloblastoma[47][48][49][50]. Germline PTCH1 mutations are associated with the nevoid basal cell carcinoma syndrome (NBCCS, Gorlin syndrome), predisposing patients to basal cell carcinoma and medulloblastoma[48]. PTCH1 is a haploinsufficient tumor suppressor gene with one copy loss may be sufficient to promote tumor development in mice[45][51].

Therapeutic and prognostic relevance

Vismodegib and sonidegib are small molecule inhibitors of SMO approved by the U.S. FDA for the treatment of patients with basal cell carcinoma[52][53][54][55].A heavily pretreated patient with metastatic medulloblastoma harboring loss-of-heterozygosity and somatic mutation of PTCH1 showed rapid regression of the tumor after treated with vismodegib[56]. Furthermore, a phase II study demonstrated that vismodegib treatment results in extended progression-free survival (PFS) in patients with loss-of-heterozygosity, SHH-driven medulloblastoma[57]. In the phase II MyPathway trial, three advanced solid tumors patients harboring PTCH1 loss-of-function mutations had partial responses to vismodegib treatment[58]. In a clinical study, two patients with Sonic Hedgehog (SHH) activated medulloblastoma harboring PTCH1 loss-of-function mutations demonstrated partial responses to sonidegib treatment[59].

RB1 Heterozygous deletion

Biological Impact

The Retinoblastoma (RB1) gene encodes a tumor suppressor that negatively regulates the cell cycle, cell division, and DNA replication[60]. Loss-of-function RB1 could lead to unregulated cell division and growth, abrogation of multiple mechanisms that safeguard against cellular transformation, and tumorigenesis[61]. RB1 has also been implicated as a haploinsufficient tumor suppressor with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological functions[62][63][64]. Deletion or inactivating mutation of RB1 is found in a number of tumors, including lung, prostate, bladder, breast cancers and sarcomas. RB1 mutations are found in approximately half of all retinoblastoma cases[65].

Therapeutic and prognostic relevance

A deleterious mutation in one or more of the three DNA repair genes ATM, RB1, and FANCC predicted pathologic response and better overall survival to cisplatin-based chemotherapy for muscle-invasive bladder cancer patients[66]. High RB loss was found to be associated with improved pathologic clinical response in breast cancer patients treated with 5-fluorouracil/adriamycin/cytoxan (FAC), T/FAC, and Taxane/Adriamycin neoadjuvant therapy[67].

Clinical and experimental data suggested that a non-functional retinoblastoma pathway is associated with resistance to tamoxifen in breast cancer[68][69].

Acquired RB1 mutations were found in hormone receptor positive breast cancer patients who developed resistance to palbociclib or ribociclib treatment[70]. Preclinical data also showed that knockdown of RB1 would impair antitumor activity of CDK4/6 inhibitor, abemaciclib[71].

Two large-scale genome-sequencing projects have identified a high prevalence of mutations in TP53 and RB1 in small cell lung cancer (SCLC)[72][73]. Analyses of repeat biopsy samples from patients with EGFR-mutant adenocarcinoma that had transformed to the SCLC subtype have revealed that 100% of these patients have loss of RB1 and may be the alteration that induces this non-small-cell to small-cell transformation[69][74].

ACT Onco® + Report

TSC1 Heterozygous deletion

Biological Impact

The tuberous sclerosis complex 1 (TSC1) gene encodes a tumor suppressor, hamartin, a key negative regulator of the mammalian target of rapamycin (mTOR) pathway[75][76]. Mutations in TSC1/TSC2 tumor suppressor genes that result in inactivation of the complex are commonly found in patients with tuberous sclerosis[77][78][79], while LOH in TSC1/TSC2 has been identified in head and neck squamous cell carcinoma (HNSCC)[80]and endometrial cancer[81]. Loss of single TSC1 allele (haploinsufficiency) may provide a growth advantage to bladder epithelial cells, contributing to bladder cancer development[82]. Both TSC1 and TSC2 mutations cause the autosomal dominant genetic disorder tuberous sclerosis complex (TSC), in which individuals develop a variety of benign but often progressive neoplasms[83].

Therapeutic and prognostic relevance

Everolimus is FDA-approved for treating Tuberous Sclerosis Complex (TSC)-associated renal angiomyolipoma and Tuberous Sclerosis Complex (TSC)-associated subependymal giant cell astrocytoma (SEGA).

TSC1/2 mutation/loss has been selected as an inclusion criteria for the trials examining temsirolimus efficacy in mutiple cancer types (NCT02693535, NCT03297606).

TSC1/TSC2 genomic alterations activate the mTOR signaling pathway and confer sensitivity to mTOR inhibitors, including everolimus, sirolimus, and temsirolimus. Everolimus is effective in multiple cancers, such as bladder tumors, gastric, sarcoma, thyroid cancer, and HNSCC[84][85]. Sirolimus is effective in treating malignant uterine PEComa with TSC1/TSC2 mutations/deletions[86][87][88], while temsirolimus is effective in those with hyperactivated mTOR pathway[89]. In advanced endometrial cancer, TSC1, and TSC2 mutations may predict clinical benefits from Temsirolimus with or without megestrol acetate and tamoxifen[90].

TSC2 Heterozygous deletion

Biological Impact

The tuberous sclerosis complex 2 (TSC2) gene encodes a protein called tuberin, which interact with a protein called hamartin (encoded by the TSC1 gene). This hamartin-tuberin tumor suppressor complex plays a critical role in growth control as a negative regulator of the mammalian target of rapamycin (mTOR) pathway[75][76]. Mutations in TSC1/TSC2 tumor suppressor genes that result in inactivation of the complex are commonly found in patients with tuberous sclerosis complex[77][78][79], while the loss of heterozygosity (LOH) in TSC1/TSC2 has been identified in head and neck squamous cell carcinoma (HNSCC)[80]and endometrial cancer[81]. TSC2 deletion, splicing-mutant, and inactivating mutations such as A1141T, G305V, S1514X, and R1032X, has been identified in TSC2-null hepatocellular carcinoma (HCC) cell lines, patient-derived xenograft, and primary tumors. Mutations in the TSC1 and TSC2 genes cause the autosomal dominant genetic disorder tuberous sclerosis complex (TSC)[83].

Therapeutic and prognostic relevance

Everolimus is FDA-approved for treating Tuberous Sclerosis Complex (TSC)-associated renal angiomyolipoma and Tuberous Sclerosis Complex (TSC)-associated subependymal giant cell astrocytoma (SEGA).

TSC1/2 mutation/loss has been selected as an inclusion criteria for the trials examining temsirolimus efficacy in mutiple cancer types (NCT02693535, NCT03297606).

ACT Onco® + Report

TSC1/TSC2 genomic alterations activate the mTOR signaling pathway and confer sensitivity to mTOR inhibitors, including everolimus, sirolimus, and temsirolimus. Everolimus is effective in multiple cancers, such as bladder tumors, gastric, sarcoma, thyroid cancer, and HNSCC[84][85]. Sirolimus is effective in treating malignant uterine PEComa with TSC1/TSC2 mutations/deletions[86][87][88], while temsirolimus is effective in those with hyperactivated mTOR pathway[89]. In advanced endometrial cancer, TSC1, and TSC2 mutations may predict clinical benefits from temsirolimus with or without megestrol acetate and tamoxifen[90].

ACT Onco® + Report

US FDA-APPROVED DRUG(S)

Everolimus (AFINITOR)

Everolimus, a derivative of sirolimus, works as an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) and blocks mTORC1-mediated downstream signals for cell growth, proliferation, and survival. Everolimus is developed and marketed by Novartis under the trade name AFINITOR.

- FDA Approval Summary of Everolimus (AFINITOR)

RADIANT-4[91] NCT01524783	**Lung or gastrointestinal neuroendocrine tumor** (Approved on 2016/02/26)
	-
	Everolimus vs. Placebo [PFS(M): 11 vs. 3.9]
BOLERO-2[92] NCT00863655	**Breast cancer** (Approved on 2012/07/20)
	ER+/HER2-
	Everolimus + exemestane vs. Placebo + exemestane [PFS(M): 7.8 vs. 3.2]
EXIST-2 NCT00790400	**Tuberous sclerosis complex (tsc)-associated renal angiomyolipoma** (Approved on 2012/04/26)
	-
	Everolimus vs. Placebo [ORR(%): 41.8 vs. 0]
RADIANT-3[93] NCT00510068	**Pancreatic neuroendocrine tumor** (Approved on 2011/05/05)
	-
	Everolimus vs. Placebo [PFS(M): 11 vs. 4.6]
EXIST-1[94] NCT00789828	**Subependymal giant cell astrocytoma** (Approved on 2010/10/29)
	-
	Everolimus vs. Placebo [ORR(%): 35.0]
RECORD-1[95] NCT00410124	**Renal cell carcinoma** (Approved on 2009/05/30)
	-
	Everolimus vs. Placebo [PFS(M): 4.9 vs. 1.9]

Niraparib (ZEJULA)

Niraparib is an oral, small molecule inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1 and -2 (PARP-1, -2). Niraparib is developed and marketed by Tesaro under the trade name ZEJULA.

- FDA Approval Summary of Niraparib (ZEJULA)

PRIMA NCT02655016	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2020/04/29)
	-
	Niraparib vs. Placebo [PFS (overall population)(M): 13.8 vs. 8.2]
NOVA[96] NCT01847274	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2017/03/27)
	-
	Niraparib vs. Placebo [PFS (overall population)(M): 11.3 vs. 4.7]

ACT Onco® + Report

Olaparib (LYNPARZA)

Olaparib is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase-1, -2, and -3 (PARP-1, -2, -3). Olaparib is developed by KuDOS Pharmaceuticals and marketed by AstraZeneca under the trade name LYNPARZA.

- FDA Approval Summary of Olaparib (LYNPARZA)

PROpel NCT03732820	**Prostate cancer** (Approved on 2023/05/31)
	BRCA mutation
	Olaparib + abiraterone + prednisone vs. Placebo + abiraterone + prednisone [rPFS(M): not reached vs. 8]
OlympiA NCT02032823	**Her2-negative high-risk early breast cancer** (Approved on 2022/03/11)
	HER2-/gBRCA mutation
	Olaparib vs. Placebo [invasive disease-free survival (IDFS)(M):]
PROfound[97] NCT02987543	**Prostate cancer** (Approved on 2020/05/19)
	HRR genes mutation
	Olaparib vs. Enzalutamide or abiraterone acetate [PFS(M): 5.8 vs. 3.5]
PAOLA-1[98] NCT02477644	**Ovarian cancer** (Approved on 2020/05/08)
	HRD+
	Olaparib + bevacizumab vs. Placebo + bevacizumab [PFS(M): 37.2 vs. 17.7]
POLO[99] NCT02184195	**Pancreatic adenocarcinoma** (Approved on 2019/12/27)
	gBRCA mutation
	Olaparib vs. Placebo [ORR(%): 23.0 vs. 12.0, PFS(M): 7.4 vs. 3.8]
SOLO-1[100] NCT01844986	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2018/12/19)
	gBRCA mutation or sBRCA mutation
	Olaparib vs. Placebo [PFS(M): NR vs. 13.8]
OlympiAD[101] NCT02000622	**Breast cancer** (Approved on 2018/02/06)
	HER2-/gBRCA mutation
	Olaparib vs. Chemotherapy [PFS(M): 7 vs. 4.2]
SOLO-2/ENGOT-Ov21[102] NCT01874353	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2017/08/17)
	gBRCA mutation
	Olaparib vs. Placebo [PFS(M): 19.1 vs. 5.5]
Study19[103] NCT00753545	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2017/08/17)
	-
	Olaparib vs. Placebo [PFS(M): 8.4 vs. 4.8]

Rucaparib (RUBRACA)

Rucaparib is an inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1, -2 and -3 (PARP-1, -2, -3). Rucaparib is developed and marketed by Clovis Oncology under the trade name RUBRACA.

- FDA Approval Summary of Rucaparib (RUBRACA)

TRITON2 NCT02952534	**Prostate cancer** (Approved on 2020/05/15)
	gBRCA mutation or sBRCA mutation
	Rucaparib [ORR(%): 44.0, DOR(M): NE]

ARIEL3[104] NCT01968213	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2018/04/06)
	-
	Rucaparib vs. Placebo [PFS (All)(M): 10.8 vs. 5.4, PFS (HRD)(M): 13.6 vs. 5.4, PFS (tBRCA)(M): 16.6 vs. 5.4]

Sonidegib (ODOMZO)

Sonidegib is a Hedgehog signaling pathway inhibitor by blocking its key component, smoothened (smo). Sonidegib is developed and marketed by Novartis under the trade name ODOMZO.

- FDA Approval Summary of Sonidegib (ODOMZO)

BOLT[54] NCT01327053	**Basal cell carcinoma** (Approved on 2015/07/24)
	-
	Sonidegib [ORR(%): 58.0]

Talazoparib (TALZENNA)

Talazoparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2. Talazoparib is developed and marketed by Pfizer under the trade name TALZENNA.

- FDA Approval Summary of Talazoparib (TALZENNA)

TALAPRO-2 NCT03395197	**Prostate cancer** (Approved on 2023/06/20)
	HRR genes mutation
	Talazoparib + enzalutamide vs. Placebo + enzalutamide [rPFS(M): Not reached vs. 13.8]
EMBRACA[105] NCT01945775	**Breast cancer** (Approved on 2018/10/16)
	HER2-/gBRCA mutation
	Talazoparib vs. Chemotherapy [PFS(M): 8.6 vs. 5.6]

Temsirolimus (TORISEL)

Temsirolimus is a soluble ester of sirolimus (rapamycin, brand-name drug Rapamune) and functions as an inhibitor of mammalian target of rapamycin complex (mTORC). The inhibitory molecular mechanism is similar to Everolimus. Temsirolimus is developed by Wyeth Pharmaceuticals and marketed by Pfizer under the trade name TORISEL.

- FDA Approval Summary of Temsirolimus (TORISEL)

[106] NCT00065468	**Renal cell carcinoma** (Approved on 2007/05/30)
	-
	Temsirolimus vs. Ifn-α [OS(M): 10.9 vs. 7.3]

ACT Onco® + Report

Vismodegib (ERIVEDGE)

Vismodegib is a cyclopamine-competitive antagonist and acts as a first-in-class Hedgehog signaling pathway inhibitor by blocking its key component smoothened (smo). Vismodegib is developed by Genentech and marketed by Roche under the trade name ERIVEDGE.

- FDA Approval Summary of Vismodegib (ERIVEDGE)

ERIVANCE BCC[52] NCT00833417	**Basal cell carcinoma** (Approved on 2012/01/30)
	-
	Vismodegib [ORR (mBCC)(%): 30.3, ORR (laBCC)(%): 42.9]

D=day; W=week; M=month

ACT Onco® + Report

ONGOING CLINICAL TRIALS

Trials were searched by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit https://clinicaltrials.gov to search and view for a complete list of open available and updated matched trials.

No trial has been found.

ACT Onco® + Report

SUPPLEMENTARY INFORMATION OF TESTING RESULTS

DETAILED INFORMATION OF VARIANTS WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
BAP1	Q392*	12	c.1174C>T	NM_004656	COSM6958162	24.3%	914
PBRM1	Splice donor	-	c.138+1G>C	NM_018313	-	18.9%	671

- Copy Number Alterations

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.



ACT Onco® + Report

OTHER DETECTED VARIANTS

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
ADAMTS9	R1459Q	29	c.4376G>A	NM_182920	COSM7662835	33.9%	1118
CBL	D460dup	9	c.1380_1382dup	NM_005188	COSM4669520	51.2%	2550
INSR	T1282A	22	c.3844A>G	NM_000208	-	46.8%	1601
KMT2D	R263C	6	c.787C>T	NM_003482	-	52.2%	1629
KMT2D	R4288Q	39	c.12863G>A	NM_003482	COSM2006804	51.0%	764
NF1	P678L	18	c.2033C>T	NM_001042492	-	45.3%	1623
NSD1	K1786R	16	c.5357A>G	NM_022455	-	49.4%	1416
PIK3C2B	Splice region	3	c.933G>T	NM_002646	-	49.6%	645
PRKN	M458L	12	c.1372A>C	NM_004562	-	34.5%	2475
RAD52	E145K	6	c.433G>A	NM_134424	-	54.6%	617
RECQL4	W379R	6	c.1135T>C	NM_004260	-	42.2%	848
RET	G568S	9	c.1702G>A	NM_020975	COSM7455374	50.1%	723
USH2A	H340R	6	c.1019A>G	NM_206933	-	49.2%	835
ZNF217	P417L	1	c.1250C>T	NM_006526	-	53.2%	2534

Note:

- This table enlists variants detected by the panel other than those with clinical relevance (reported in Testing Result section). The clinical impact of a genetic variant is determined according to ACT Genomics in-house clinical knowledge database. A negative result does not necessarily indicate absence of biological effect on the tumor. Some variants listed here may possibly have preclinical data or may show potential clinical relevance in the future.

ACT Onco® + Report

TEST DETAILS

SPECIMEN RECEIVED AND PATHOLOGY REVIEW





- Collection date: Dec 29, 2022
- Facility retrieved: 振興醫院
- H&E-stained section No.: 11122499F
- Collection site: Liver
- Examined by: Dr. Yun-An Chen
    1. The percentage of viable tumor cells in total cells in the whole slide (%): 30%
    2. The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 75%
    3. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 0%
    4. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 0%
    5. Additional comment: NA
- Manual macrodissection: Performed on the highlighted region
- The outline highlights the area of malignant neoplasm annotated by a pathologist.

RUN QC

- Panel: ACTOnco®+

DNA test

- Mean Depth: 1101x
- Target Base Coverage at 100x: 95%

RNA test

- Average unique RNA Start Sites per control GSP2: 150

ACT Onco® + Report

LIMITATIONS

1. This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.
2. The possibility cannot be excluded that certain pathogenic variants detected by other sequencing tools may not be reported in the test because of technical limitation of bioinformatics algorithm or the NGS sequencing platform, e.g. low coverage.
3. This test has been designed to detect fusions in 13 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

NEXT-GENERATION SEQUENCING (NGS) METHODS

DNA test

Extracted genomic DNA was amplified using primers targeting coding exons of analyzed genes and subjected to library construction. Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite. Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (InDels) were identified using the Torrent Variant Caller plug-in. VEP (Variant Effect Predictor) was used to annotate every variant using databases from Clinvar, COSMIC and Genome Aggregation database. Variants with coverage ≥ 20, allele frequency ≥ 5% and actionable variants with allele frequency ≥ 2% were retained. This test provides uniform coverage of the targeted regions, enabling target base coverage at 100x ≥ 85% with a mean coverage ≥ 500x.

Variants reported in Genome Aggregation database with > 1% minor allele frequency (MAF) were considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number alterations (CNAs) were predicted as described below:
Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation ≥ 0.3 were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco®+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as "TMB-High", "TMB-Low" or "Cannot Be Determined". TMB-High corresponds to ≥ 7.5 mutations per megabase (Muts/Mb); TMB-Low corresponds to < 7.5 Muts/Mb. TMB is reported as "Cannot Be Determined" if the tumor purity of the sample is < 30%.

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in > 400 genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

ACT Onco® + Report

RNA test

Extracted RNA was reverse-transcribed and subjected to library construction. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific). To ensure sequencing quality for fusion variant analysis, the average unique RNA Start Sites (SS) per control Gene Specific Primer 2 (GSP 2) should be ≥ 10.

The fusion analysis pipeline aligned sequenced reads to the human reference genome, identified regions that map to noncontiguous regions of the genome, applied filters to exclude probable false-positive events and, annotated previously characterized fusion events according to Quiver Gene Fusion Database, a curated database owned and maintained by ArcherDX. In general, samples with detectable fusions need to meet the following criteria: (1) Number of unique start sites (SS) for the GSP2 ≥ 3; (2) Number of supporting reads spanning the fusion junction ≥ 5; (3) Percentage of supporting reads spanning the fusion junction ≥ 10%; (4) Fusions annotated in Quiver Gene Fusion Database.

DATABASE USED

- Reference genome: Human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210404)
- ACT Genomics in-house database
- Quiver Gene Fusion Database version 5.1.18

Variant Analysis:
醫檢師張筑芃 博士
Chu-Yuan Chang Ph.D.
檢字第 020115 號

Sign Off
解剖病理專科醫師王業翰
Yeh-Han Wang M.D.
病解字第 000545 號

ACT Onco® + Report

GENE LIST

SNV & CNV

ABCB1*	ABCC2*	ABCG2*	ABL1	ABL2	ADAMTS1	ADAMTS13	ADAMTS15	ADAMTS16	ADAMTS18	ADAMTS6	ADAMTS9
ADAMTSL1	ADGRA2	ADH1C*	AKT1	AKT2	AKT3	ALDH1A1*	ALK	AMER1	APC	AR	ARAF
ARID1A	ARID1B	ARID2	ASXL1	ATM	ATR	ATRX	AURKA	AURKB	AXIN1	AXIN2	AXL
B2M	BAP1	BARD1	BCL10	BCL2*	BCL2L1	BCL2L2*	BCL6	BCL9	BCOR	BIRC2	BIRC3
BLM	BMPR1A	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2*	BTK	BUB1B	CALR
CANX	CARD11	CASP8	CBFB	CBL	CCNA1	CCNA	CCNB1	CCNB2	CCNB3	CCND1	CCND2
CCND3	CCNE1	CCNE2	CCNH	CD19	CD274	CD58	CD70*	CD79A	CD79B	CDC73	CDH1
CDK1	CDK12	CDK2	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDKN1A	CDKN1B	CDKN2A
CDKN2B	CDKN2C	CEBPA*	CHEK1	CHEK2	CIC	CREBBP	CRKL	CRLF2	CSF1R	CTCF	CTLA4
CTNNA1	CTNNB1	CUL3	CYLD	CYP1A1*	CYP2B6*	CYP2C19*	CYP2C8*	CYP2D6	CYP2E1*	CYP3A4*	CYP3A5*
DAXX	DCUN1D1	DDR2	DICER1	DNMT3A	DOT1L	DPYD	DTX1	E2F3	EGFR	EP300	EPCAM
EPHA2	EPHA3	EPHA5	EPHA7	EPHB1	ERBB2	ERBB3	ERBB4	ERCC1	ERCC2	ERCC3	ERCC4
ERCC5	ERG	ESR1	ESR2	ETV1	ETV4	EZH2	FAM46C	FANCA	FANCC	FANCD2	FANCE
FANCF	FANCG	FANCL	FAS	FAT1	FBXW7	FCGR2B	FGF1*	FGF10	FGF14	FGF19*	FGF23
FGF3	FGF4*	FGF6	FGFR1	FGFR2	FGFR3	FGFR4	FH	FLCN	FLT1	FLT3	FLT4
FOXL2*	FOXP1	FRG1	FUBP1	GATA1	GATA2	GATA3	GNA11	GNA13	GNAQ	GNAS	GREM1
GRIN2A	GSK3B	GSTP1*	GSTT1*	HGF	HIF1A	HIST1H1C*	HIST1H1E*	HNF1A	HR	HRAS*	HSP90AA1
HSP90AB1	HSPA4	HSPA5	IDH1	IDH2	IFNL3*	IGF1	IGF1R	IGF2	IKBKB	IKBKE	IKZF1
IL6	IL7R	INPP4B	INSR	IRF4	IRS1	IRS2*	JAK1	JAK2	JAK3	JUN*	KAT6A
KDM5A	KDM5C	KDM6A	KDR	KEAP1	KIT	KMT2A	KMT2C	KMT2D	KRAS	LCK	LIG1
LIG3	LMO1	LRP1B	LYN	MALT1	MAP2K1	MAP2K2	MAP2K4	MAP3K1	MAP3K7	MAPK1	MAPK3
MAX	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MET	MITF	MLH1	MPL	MRE11
MSH2	MSH6	MTHFR*	MTOR	MUC16	MUC4	MUC6	MUTYH	MYC	MYCL	MYCN	MYD88
NAT2*	NBN	NEFH	NF1	NF2	NFE2L2	NFKB1	NFKBIA	NKX2-1*	NOTCH1	NOTCH2	NOTCH3
NOTCH4	NPM1	NQO1*	NRAS	NSD1	NTRK1	NTRK2	NTRK3	PAK3	PALB2	PARP1	PAX5
PAX8	PBRM1	PDCD1	PDCD1LG2	PDGFRA	PDGFRB	PDIA3	PGF	PHOX2B*	PIK3C2B	PIK3C2G	PIK3C3
PIK3CA	PIK3CB	PIK3CD	PIK3CG	PIK3R1	PIK3R2	PIK3R3	PIM1	PMS1	PMS2	POLB	POLD1
POLE	PPARG	PPP2R1A	PRDM1	PRKAR1A	PRKCA	PRKCB	PRKCG	PRKCI	PRKCQ	PRKDC	PRKN
PSMB8	PSMB9	PSME1	PSME2	PSME3	PTCH1	PTEN	PTGS2	PTPN11	PTPRD	PTPRT	RAC1
RAD50	RAD51	RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	RECQL4
REL	RET	RHOA	RICTOR	RNF43	ROS1	RPPH1	RPTOR	RUNX1	RUNX1T1	RXRA	SDHA
SDHB	SDHC	SDHD	SERPINB3	SERPINB4	SETD2	SF3B1	SGK1	SH2D1A*	SLC19A1*	SLC22A2*	SLCO1B1*
SLCO1B3*	SMAD2	SMAD3	SMAD4	SMARCA4	SMARCB1	SMO	SOCS1*	SOX2*	SOX9	SPEN	SPOP
SRC	STAG2	STAT3	STK11	SUFU	SYK	SYNE1	TAF1	TAP1	TAP2	TAPBP	TBX3
TEK	TERT	TET1	TET2	TGFBR2	TMSB4X*	TNF	TNFAIP3	TNFRSF14	TNFSF11	TOP1	TP53
TPMT*	TSC1	TSC2	TSHR	TYMS	U2AF1	UBE2A*	UBE2K	UBR5	UGT1A1*	USH2A	VDR*
VEGFA	VEGFB	VHL	WT1	XIAP	XPO1	XRCC2	ZNF217				

*Analysis of copy number alterations NOT available.

FUSION

ALK	BRAF	EGFR	FGFR1	FGFR2	FGFR3	MET	NRG1	NTRK1	NTRK2	NTRK3	RET	ROS1

ACT Onco® + Report

APPENDIX

POSSIBLE THERAPEUTIC IMPLICATIONS FOR HETEROZYGOUS DELETION

Gene	Therapies	Possible effect
FBXW7	Everolimus, Temsirolimus	**sensitive**
TSC1	Everolimus, Temsirolimus	**sensitive**
TSC2	Everolimus, Temsirolimus	**sensitive**
BRCA2	Niraparib, Olaparib, Rucaparib, Talazoparib	**sensitive**
PTCH1	Sonidegib, Vismodegib	**sensitive**
RB1	Abemaciclib, Palbociclib, Ribociclib	**resistant**
FBXW7	Gefitinib, Regorafenib	**resistant**

SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS



1: Olaparib, Niraparib, Rucaparib, Talazoparib

ACT Onco® + Report



1: Sonidegib, Vismodegib



1: Everolimus, Temsirolimus

ACT Onco® + Report

DISCLAIMER

法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。
本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。
本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

ACT Onco® + Report

REFERENCE

1. PMID: 20302916; 2010, Biochim Biophys Acta;1806(1):1-6
The potential role of ubiquitin c-terminal hydrolases in oncogenesis.

2. PMID: 21642991; 2011, Nat Genet;43(7):668-72
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

3. PMID: 19188440; 2009, Mol Cell Biol;29(8):2181-92
Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1.

4. PMID: 18757409; 2008, Cancer Res;68(17):6953-62
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.

5. PMID: 26891804; 2016, Int J Oncol;48(4):1571-80
Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.

6. PMID: 21051595; 2010, Science;330(6009):1410-3
Frequent mutation of BAP1 in metastasizing uveal melanomas.

7. PMID: 24128712; 2013, J Thorac Oncol;8(11):1430-3
Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.

8. PMID: 22683710; 2012, Nat Genet;44(7):751-9
BAP1 loss defines a new class of renal cell carcinoma.

9. PMID: 23333114; 2013, Lancet Oncol;14(2):159-167
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.

10. PMID: 24185509; 2013, Nat Genet;45(12):1470-1473
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.

11. PMID: 25889843; 2015, J Transl Med;13():122
BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.

12. PMID: 33515503; 2021, Lancet Respir Med;9(6):593-600
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.

13. PMID: 28389374; 2017, J Thorac Oncol;12(8):1309-1319
A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.

14. PMID: 19234488; 2009, Oncogene;28(14):1653-68
The SWI/SNF complex and cancer.

15. PMID: 24613357; 2014, Cell Rep;6(6):973-981
BAF180 promotes cohesion and prevents genome instability and aneuploidy.

16. PMID: 23867514; 2013, Cancer J;19(4):324-32
PBRM1 and BAP1 as novel targets for renal cell carcinoma.

17. PMID: 10897333; 2000, Mol Pathol;53(3):137-44
Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis.

18. PMID: 29301960; 2018, Science;359(6377):801-806
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.

19. PMID: 30150660; 2018, Nat Genet;50(9):1271-1281

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.

20. PMID: 26003625; 2015, Urol Oncol;33(8):340.e9-16
Decreased PBRM1 expression predicts unfavorable prognosis in patients with clear cell renal cell carcinoma.

21. PMID: 11239455; 2001, Mol Cell;7(2):263-72
BRCA2 is required for homology-directed repair of chromosomal breaks.

22. PMID: 17597348; 2007, Ann Surg Oncol;14(9):2510-8
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.

23. PMID: 22193408; 2011, Nat Rev Cancer;12(1):68-78
BRCA1 and BRCA2: different roles in a common pathway of genome protection.

24. PMID: 27283171; 2016, J Natl Compr Canc Netw;14(6):795-806
The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling?

25. PMID: 15498494; 2004, Curr Biol;14(20):1852-7
A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size.

26. PMID: 15103331; 2004, EMBO J;23(10):2116-25
Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7.

27. PMID: 16023596; 2005, Cancer Cell;8(1):25-33
The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase.

28. PMID: 11533444; 2001, Science;294(5540):173-7
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase.

29. PMID: 11461910; 2001, J Biol Chem;276(38):35847-53
The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog.

30. PMID: 11425854; 2001, J Biol Chem;276(37):34371-8
Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor.

31. PMID: 16863506; 2006, Cancer Sci;97(8):729-36
Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation.

32. PMID: 18787170; 2008, Science;321(5895):1499-502
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.

33. PMID: 20484041; 2010, Cancer Res;70(11):4728-38
The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation.

34. PMID: 21368833; 2011, Nature;471(7336):104-9
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.

35. PMID: 18094723; 2008, Nat Rev Cancer;8(2):83-93
FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation.

36. PMID: 23032637; 2012, Cancer Inform;11():157-71
Haploinsufficiency of Tumor Suppressor Genes is Driven by the Cumulative Effect of microRNAs, microRNA Binding Site Polymorphisms and microRNA Polymorphisms: An In silico Approach.

37. PMID: 24586741; 2014, PLoS One;9(2):e89388
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.

38. PMID: 24360397; 2014, Lung Cancer;83(2):300-1
Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation.

ACT Onco® + Report

39. PMID: 27399335; 2017, Oncogene;36(6):787-796
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.

40. PMID: 25860929; 2015, Oncotarget;6(11):9240-56
FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.

41. PMID: 29633504; 2018, Mol Oncol;12(6):883-895
FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.

42. PMID: 28522751; 2017, Cancer Res;77(13):3527-3539
Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer.

43. PMID: 24884509; 2014, Mol Cancer;13():110
Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.

44. PMID: 8906794; 1996, Nature;384(6605):176-9
Biochemical evidence that patched is the Hedgehog receptor.

45. PMID: 12016144; 2002, Carcinogenesis;23(5):727-33
Unbalanced overexpression of the mutant allele in murine Patched mutants.

46. PMID: 11130178; 2000, Cell Mol Life Sci;57(12):1720-31
Hedgehog signalling in cancer.

47. PMID: 8782823; 1996, Nat Genet;14(1):78-81
The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas.

48. PMID: 8658145; 1996, Science;272(5268):1668-71
Human homolog of patched, a candidate gene for the basal cell nevus syndrome.

49. PMID: 9422511; 1998, Nature;391(6662):90-2
Activating Smoothened mutations in sporadic basal-cell carcinoma.

50. PMID: 22832583; 2012, Nature;488(7409):100-5
Dissecting the genomic complexity underlying medulloblastoma.

51. PMID: 10738305; 2000, Genes Chromosomes Cancer;28(1):77-81
Evidence that haploinsufficiency of Ptch leads to medulloblastoma in mice.

52. PMID: 22670903; 2012, N Engl J Med;366(23):2171-9
Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

53. PMID: 28511673; 2017, BMC Cancer;17(1):332
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

54. PMID: 25981810; 2015, Lancet Oncol;16(6):716-28
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

55. PMID: 31545507; 2020, Br J Dermatol;182(6):1369-1378
Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.

56. PMID: 19726761; 2009, N Engl J Med;361(12):1173-8
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.

57. PMID: 26169613; 2015, J Clin Oncol;33(24):2646-54
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain

Tumor Consortium Studies PBTC-025B and PBTC-032.

58. PMID: 29320312; 2018, J Clin Oncol;36(6):536-542
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

59. PMID: 34409296; 2021, Neurooncol Adv;3(1):vdab097
Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma.

60. PMID: 22293180; 2012, J Clin Invest;122(2):425-34
Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.

61. PMID: 6320372; 1984, Science;223(4640):1028-33
Retinoblastoma: clues to human oncogenesis.

62. PMID: 27308386; 2015, Mol Cell Oncol;2(1):e968069
Conditional haploinsufficiency of the retinoblastoma tumor suppressor gene.

63. PMID: 23687339; 2013, Cancer Res;73(14):4247-55
Rb1 haploinsufficiency promotes telomere attrition and radiation-induced genomic instability.

64. PMID: 28169375; 2017, Sci Rep;7():42056
The Rb1 tumour suppressor gene modifies telomeric chromatin architecture by regulating TERRA expression.

65. PMID: 15884040; 2005, Hum Mutat;25(6):566-74
Sensitive multistep clinical molecular screening of 180 unrelated individuals with retinoblastoma detects 36 novel mutations in the RB1 gene.

66. PMID: 26238431; 2015, Eur Urol;68(6):959-67
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.

67. PMID: 22811582; 2012, Clin Cancer Res;18(18):5110-22
RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer.

68. PMID: 21358261; 2011, Cell Cycle;10(6):956-62
A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen.

69. PMID: 17160137; 2007, J Clin Invest;117(1):218-28
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.

70. PMID: 29236940; 2018, Ann Oncol;29(3):640-645
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.

71. PMID: 29483214; 2018, Mol Cancer Ther;17(5):897-907
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer.

72. PMID: 22941188; 2012, Nat Genet;44(10):1104-10
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.

73. PMID: 22941189; 2012, Nat Genet;44(10):1111-6
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.

74. PMID: 25846096; 2015, Lancet Oncol;16(4):e165-72
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

75. PMID: 21157483; 2011, Nat Rev Mol Cell Biol;12(1):21-35
mTOR: from growth signal integration to cancer, diabetes and ageing.

76. PMID: 12271141; 2002, Proc Natl Acad Sci U S A;99(21):13571-6
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.

ACT Onco® + Report

77. PMID: 9242607; 1997, Science;277(5327):805-8
Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.

78. PMID: 8269512; 1993, Cell;75(7):1305-15
Identification and characterization of the tuberous sclerosis gene on chromosome 16.

79. PMID: 1303246; 1992, Nat Genet;2(1):37-41
Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease.

80. PMID: 18538015; 2008, BMC Cancer;8():163
Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma.

81. PMID: 28339086; 2017, Int J Oncol;50(5):1778-1784
Identification of novel mutations in endometrial cancer patients by whole-exome sequencing.

82. PMID: 20610279; 2010, Urol Oncol;28(4):409-28
Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium.

83. PMID: 17005952; 2006, N Engl J Med;355(13):1345-56
The tuberous sclerosis complex.

84. PMID: 22923433; 2012, Science;338(6104):221
Genome sequencing identifies a basis for everolimus sensitivity.

85. PMID: 26859683; 2016, Oncotarget;7(9):10547-56
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.

86. PMID: 20048174; 2010, J Clin Oncol;28(5):835-40
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.

87. PMID: 34637337; 2021, J Clin Oncol;39(33):3660-3670
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors.

88. PMID: 34442003; 2021, J Clin Med;10(16):
Efficacy of Sirolimus Treatment in PEComa-10 Years of Practice Perspective.

89. PMID: 20215136; 2010, Ann Oncol;21(5):1135-7
Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa.

90. PMID: 27016228; 2016, Gynecol Oncol;141(1):43-8
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.

91. PMID: 26703889; 2016, Lancet;387(10022):968-977
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

92. PMID: 22149876; 2012, N Engl J Med;366(6):520-9
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

93. PMID: 21306238; 2011, N Engl J Med;364(6):514-23
Everolimus for advanced pancreatic neuroendocrine tumors.

94. PMID: 23158522; 2013, Lancet;381(9861):125-32
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

95. PMID: 18653228; 2008, Lancet;372(9637):449-56

ACT Onco® + Report

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

96. PMID: 27717299; 2016, N Engl J Med;375(22):2154-2164
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

97. PMID: 32343890; 2020, N Engl J Med;382(22):2091-2102
Olaparib for Metastatic Castration-Resistant Prostate Cancer.

98. PMID: 31851799; 2019, N Engl J Med;381(25):2416-2428
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

99. PMID: 31157963; 2019, N Engl J Med;381(4):317-327
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

100. PMID: 30345884; 2018, N Engl J Med;379(26):2495-2505
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

101. PMID: 28578601; 2017, N Engl J Med;377(6):523-533
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

102. PMID: 28754483; 2017, Lancet Oncol;18(9):1274-1284
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

103. PMID: 27617661; 2016, Lancet Oncol;17(11):1579-1589
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

104. PMID: 28916367; 2017, Lancet;390(10106):1949-1961
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

105. PMID: 30110579; 2018, N Engl J Med;379(8):753-763
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

106. PMID: 17538086; 2007, N Engl J Med;356(22):2271-81
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.